• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Read More
Dave Lennon, PhD
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

Comments

Comments are closed.

  • Next Post
  • Previous Post